Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | CDK7 | P50613 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | CCNH | P51946 | 1/20 | 0.35 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 2/20 | 0.33 |
| ▸ | CHUK | O15111 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2787055 | 0.91 | PDPK1 (0.39) | PDPK1PIM1CCNT1CCND1CCNC | |
| SCHEMBL4112718 | 0.77 | P2RX7 (0.49) | MAPK1ALDH1A1 | |
| SCHEMBL4308970 | 0.76 | RIPK1 (0.31) | PDPK1RIPK1MAPK1 | |
| Cytosine SCHEMBL29100442 | 0.74 | DYRK1A (0.38) | — | |
| SCHEMBL4102491 | 0.74 | KDM4E (0.48) | ALDH1A1LMNA | |
| SCHEMBL4309792 | 0.72 | JAK3 (0.33) | — | |
| SCHEMBL7052922 | 0.72 | KDM4E (0.32) | — | |
| Pyrrole SCHEMBL5232814 | 0.71 | LMNA (0.34) | PDPK1PIM1ALDH1A1LMNA | |
| SCHEMBL10424836 | 0.71 | PDPK1 (0.38) | PDPK1PIM1CCNT1CCND1CCNC | |
| SCHEMBL19463620 | 0.69 | PIM1 (0.43) | PDPK1PIM1CCNT1CCND1CCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023219427-A1 | NOVEL PYRROLOPYRIMIDINONE CARBOXAMIDE COMPOUND FOR INHIBITING CDK, STEREOISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING SAME AS ACTIVE INGREDIENT | 서울대학교산학협력단 | 2023-11-16 | — | — | WO | claimed |
| EP-2636677-B1 | CDK-INHIBITING PYRROLOPYRIMIDINONE CARBOXAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING LIVER CELL CANCER | SNU R&DB FOUNDATION (KR) | 2016-01-13 | — | — | EP | claimed |
| US-20130237495-A1 | CDK-INHIBITING PYRROLOPYRIMIDINONE CARBOXAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING HEPATOCELLULAR CARCINOMA | SNU R&DB FOUNDATION (KR) | 2013-09-12 | — | — | US | claimed |
| EP-2636677-A1 | CDK-INHIBITING PYRROLOPYRIMIDINONE CARBOXAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING LIVER CELL CANCER | SNU R & DB Foundation (KR) | 2013-09-11 | — | — | EP | claimed |
| WO-2023219427-A1 | NOVEL PYRROLOPYRIMIDINONE CARBOXAMIDE COMPOUND FOR INHIBITING CDK, STEREOISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING SAME AS ACTIVE INGREDIENT | 서울대학교산학협력단 | 2023-11-16 | — | — | WO | disclosed |
| WO-2023219427-A1 | NOVEL PYRROLOPYRIMIDINONE CARBOXAMIDE COMPOUND FOR INHIBITING CDK, STEREOISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING SAME AS ACTIVE INGREDIENT | 서울대학교산학협력단 | 2023-11-16 | — | — | WO | disclosed |
| EP-2636677-B1 | CDK-INHIBITING PYRROLOPYRIMIDINONE CARBOXAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING LIVER CELL CANCER | SNU R&DB FOUNDATION (KR) | 2016-01-13 | — | — | EP | disclosed |
| US-9062088-B2 | CDK-inhibiting pyrrolopyrimidine carboxamide derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing the same as active ingredient for preventing or treating hepatocellular carcinoma | SNU R&DB FOUNDATION (KR) | 2015-06-23 | — | — | US | disclosed |
| US-20130237495-A1 | CDK-INHIBITING PYRROLOPYRIMIDINONE CARBOXAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING HEPATOCELLULAR CARCINOMA | SNU R&DB FOUNDATION (KR) | 2013-09-12 | — | — | US | disclosed |
| US-20130237495-A1 | CDK-INHIBITING PYRROLOPYRIMIDINONE CARBOXAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING HEPATOCELLULAR CARCINOMA | SNU R&DB FOUNDATION (KR) | 2013-09-12 | — | — | US | disclosed |
| EP-2636677-A1 | CDK-INHIBITING PYRROLOPYRIMIDINONE CARBOXAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING LIVER CELL CANCER | SNU R & DB Foundation (KR) | 2013-09-11 | — | — | EP | disclosed |
| EP-2636677-A1 | CDK-INHIBITING PYRROLOPYRIMIDINONE CARBOXAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING LIVER CELL CANCER | SNU R & DB Foundation (KR) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012060482-A1 | CDK-INHIBITING PYRROLOPYRIMIDINONE CARBOXAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING LIVER CELL CANCER | 서울대학교 산학협력단 (KR) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237495-A1 | CDK-INHIBITING PYRROLOPYRIMIDINONE CARBOXAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING HEPATOCELLULAR CARCINOMA | CDK7, CDK4, CDK14 | PDPK1 264/4885PIM1 972/4885CCNT1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.